LH
The setup
Labcorp spent its 2026 Investor Day doing what public companies love most: painting a very pretty picture of the next few years. The company reaffirmed 2026 guidance and then went bigger, laying out a 2029 playbook built around higher-margin specialty testing, personalized health, and more automation.
The numbers behind the pep talk
For 2026, Labcorp expects adjusted EPS of $18.10 to $18.55 and sales of $14.710 billion to $14.827 billion, both a touch above Wall Street’s current read. That’s the kind of guidance that can help soothe investors who were wondering whether growth was about to take a coffee break.
Why investors should care
Management’s longer-term targets are the real headline here:
- Revenue CAGR of 5% to 8% through 2029
- Adjusted EPS CAGR of 8.5% to 11.5%
- Operating margin expansion of 75 to 150 basis points by 2029
- Free cash flow growth expected to track earnings growth
That’s a pretty clear signal that Labcorp thinks it can squeeze more juice out of the business without needing a moonshot. The company is betting big on oncology, neurology, autoimmune disease, and women’s health, while using AI and robotics to make the whole machine run faster and cheaper.
Big picture
This is less “wild reinvention” and more “quiet industrial upgrade.” If Labcorp can keep specialty testing growing and automation actually lowers friction, the stock may start to look more like a steady compounder than a sleepy health care name with lab coats and clipboards.